Given the aberrant activation of the PI3K/AKT/mTOR pro-survival pathway observed in DDLPS (55), idasanutlin was tested in combination with the PI3K/mTOR inhibitor NVP-BEZ235 resulting in enhanced cell growth inhibition, apoptotic cell death, and reduction of tumor growth rate (38). The gene discussed is AKT1; the disease is neoplasm.